Entrada Therapeutics, Inc. (TRDA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Entrada Therapeutics, Inc. ( TRDA ) Goldman Sachs 47th Annual Global Healthcare Conference 2026 June 8, 2026 8:00 AM EDT Dipal Doshi - CEO & Director Natarajan Sethuraman - President of Research & Development Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Kyuwon Choi Goldman Sachs Group, Inc., Research Division Thank you. Good morning. Thank you for joining us. I'm Paul Choi, and I cover the mid-cap biotech sector here at Goldman Sachs. Joining us here at the Goldman Sachs Global Healthcare Conference is Entrada. Before we begin, I'm required to make some certain disclosures. These disclosures pertain to investment banking and other relationships that we may have with companies discussed here at the conference. For anyone listening or who are clients at the firm that are attending, these disclosures are available to you on our research portal. We are prepared to read them aloud, but they are available for you through our Goldman Sachs Research. Kyuwon Choi Goldman Sachs Group, Inc., Research Division And with that, it's our pleasure to have Entrada here. And maybe what we'll do is start at a high level with Dipal here and maybe talk about for those who are new to the Entrada story and/or maybe the DMD space, can you maybe walk us through what is the EEV platform and what, I guess, in the earlier preclinical data has made you excited about its potential? Sure. Yes. Thanks, Paul, and thanks to the Goldman team for -- asking us to participate. So the Entrada Therapeutics story starts back in 2016. But when we start to think about what is so special about this company, it starts with the Endosomal Escape Vehicles or EEVs, which are essentially a family of cyclic cell-penetrating peptides that have these remarkable and unique properties that